Alzamend Neuro Inc
alzamend.comWhat Do They Do?
Develops a lithium cocrystal drug candidate for Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. It is also developing a cell-based vaccine candidate for Alzheimer’s disease.
10-K for FY2026, filed Jul 22, 2026We are a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease…View ↗
AL001 - A patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three…View ↗
ALZN002 - A patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of…View ↗
Our most advanced product candidate (our lead product) is AL001, an ionic cocrystal of lithium designed to treat Alzheimer’s, BD, MDD and…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2026, filed Jul 22, 2026
Who Are Their Customers?
Plans to partner with biopharmaceutical companies and established distributors or producers to fund later-stage development and sell approved products; it does not expect to sell directly to the marketplace.
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2027, filed Sep 10, 2026
−$3MView ↗
- ▲ +12% (Loss)
- vs −$2.7M in Q1 FY2026
Loading...
